## PROF Stock Surges as Profound Medical Unveils Game-Changing Prostate Treatment at Major Medical Conferences

Profound Medical Corp. (PROF) delivered significant news to the investment and medical communities this week, revealing its next-generation TULSA-AI Volume Reduction module for benign prostatic hyperplasia at two major healthcare gatherings—the Radiological Society of North America conference in Chicago and the Society for Urologic Oncology meeting in Phoenix.

**The Market Opportunity: From Niche to Mainstream**

The company's latest advancement could fundamentally reshape the prostate disease treatment landscape. BPH, an age-related enlargement affecting millions of aging men, has long been managed through procedures that haven't evolved significantly in decades. Traditional approaches like TURP carry considerable drawbacks: bleeding risks, sexual dysfunction, and extended recovery periods. Profound's intelligent Volume Reduction module sidesteps these limitations by automating procedural precision and adapting therapy to individual anatomy, regardless of gland configuration. The impact? The company projects its addressable market in prostate conditions will nearly triple, expanding to approximately 600,000 patients annually.

**Clinical Data That Speaks for Itself**

Real-world outcomes presented at RSNA demonstrate meaningful advantages. The CAPTAIN randomized controlled trial—comparing MRI-guided ablation against robotic prostatectomy—revealed superior results across multiple parameters: significantly lower blood loss, shorter hospitalization, reduced post-operative pain, and faster functional recovery. Beyond quantifiable metrics, the data showed preserved urinary continence and sexual function preservation, addressing two major patient concerns that have historically limited treatment adoption.

**Comprehensive Clinical Presentation Schedule**

RSNA attendees will access multiple educational opportunities: the CAPTAIN trial results on December 1, followed by dedicated sessions on December 2 showcasing TULSA-PRO technology and single-center outcome data from 160 organ-confined prostate cancer patients. Stanford researchers will separately present comparable trial data at SUO, reinforcing the clinical evidence base.

**Broader Therapeutic Platform Expansion**

Beyond prostate applications, Profound is advancing Sonalleve, a CE-marked platform demonstrating efficacy across multiple conditions requiring thermal ablation and symptom palliation—from uterine fibroids and adenomyosis to bone metastases pain management, desmoid tumors, and osteoid osteoma. The company is exploring additional indications in abdominal malignancies and therapeutic hyperthermia.

**The Unique Competitive Position**

TULSA-PRO stands alone as the only incision-free treatment spanning the complete prostate disease spectrum—from early cancer to advanced BPH and hybrid presentations. The single-session, radiation-free protocol with rapid recovery differentiation positions Profound distinctly against conventional surgical alternatives.

**Stock Performance and Market Reception**

PROF closed Friday's session at $6.60, reflecting a 2.17% gain. Over the trailing 12-month period, the stock has ranged between $3.76 and $8.75, tracking broader healthcare technology investor sentiment and clinical milestone achievements.